IGF-1 induced vascular endothelial growth factor secretion in head and neck squamous cell carcinoma

Biochemical and Biophysical Research Communications

Volumn 342, Issue 3, 2006, Pages 851-858

  Slomiany, Mark G ^a   Black, Leigh Ann ^a   Kibbey, Megan M ^a   Day, Terry A ^b   Rosenzweig, Steven A ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Autocrine action; IGF 1; IGFBP; Squamous cell carcinoma; VEGF

Indexed keywords

COBALT CHLORIDE; ENOLASE; ISOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; NEUROPILIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN C; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ARTICLE; CELL LINE; CONCENTRATION (PARAMETERS); HEAD AND NECK CARCINOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA;

1-PHOSPHATIDYLINOSITOL 3-KINASE; AUTOCRINE COMMUNICATION; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; COBALT; CULTURE MEDIA, CONDITIONED; HEAD AND NECK NEOPLASMS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INSULIN-LIKE GROWTH FACTOR I; MITOGEN-ACTIVATED PROTEIN KINASES; MODELS, BIOLOGICAL; RECEPTOR, IGF TYPE 1; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANS-ACTIVATION (GENETICS); VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33644615750     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.02.043     Document Type: Article

References (41)

1. M.T. Canto, and S.S. Devesa Oral cavity and pharynx cancer incidence rates in the United States Oral Oncol. 38 2002 610 617
2. N. Bouck, V. Stellmach, and S.C. Hsu How tumors become angiogenic Adv. Cancer Res. 69 1996 134 174
3. J. Folkman, K. Watson, D. Ingber, and D. Hanahan Induction of angiogenesis during the transition from hyperplasia to neoplasia Nature 339 1989 58 61
4. J. Folkman What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. 82 1990 4 6
5. R.J. Eisma, J.D. Spiro, and D.L. Kreutzer Vascular endothelial growth factor expression in head and neck squamous cell carcinoma Am. J. Surg. 174 1997 513 517
6. P. Salven, P. Heikkila, A. Anttonen, M. Kajanti, and H. Joensuu Vascular endothelial growth factor in squamous cell head and neck carcinoma: expression and prognostic significance Mod. Pathol. 10 1997 1128 1133
7. H. Mineta, K. Miura, T. Ogino, S. Takebayashi, K. Misawa, Y. Ueda, I. Suzuki, M. Dictor, A. Borg, and J. Wennerberg Prognostic value of vascular endothelial growth factor (VEGF) in head and neck squamous cell carcinomas Br. J. Cancer 83 2000 775 781
8. E.R. Sauter, M. Nesbit, J.C. Watson, A. Klein-Szanto, S. Litwin, and M. Herlyn Vascular endothelial growth factor is a marker of tumor invasion and metastasis in squamous cell carcinomas of the head and neck Clin. Cancer Res. 5 1999 775 782
9. J.A. Forsythe, B.H. Jiang, N.V. Iyer, F. Agani, S.W. Leung, R.D. Koos, and G.L. Semenza Activation of vascular endothelial growth factor gene transcription by hypoxia Mol. Cell. Biol. 16 1996 4604 4613
10. G.L. Semenza HIF-1 and tumor progression: pathophysiology and therapeutics Trends Mol. Med. 8 Suppl. 2002 S62 S67
11. P. Carmeliet, Y. Dor, J.-M. Herbert, D. Fukumura, K. Brusselmans, M. Dewerchin, M. Neeman, F. Bono, R. Abramovitch, P. Maxwell, C.J. Koch, P. Ratcliffe, L. Moons, R.K. Jain, D. Collen, and E. Keshet Role of Hif-1 alpha in hypoxia-mediated apoptosis, cell proliferation, and tumour angiogenesis Nature 394 1998 485 490
12. 2 sensing Science 292 2001 464 468
13. 2-regulated prolyl hydroxylation Science 292 2001 468 472
14. H. Zhong, A.M. DeMarzo, E. Laughner, M. Lim, D.A. Hilton, D. Zagzag, P. Buechler, W.B. Isaacs, G.L. Semenza, and J.W. Simons Overexpression of hypoxia-inducible factor 1 alpha in common human cancers and their metastases Cancer Res. 59 1999 5830 5839
15. K. Talks, H. Turley, K.C. Gatter, P.H. Maxwell, C.W. Pugh, P.J. Ratcliffe, and A.L. Harris The expression and distribution of the hypoxia inducible factors Hif-1 alpha and Hif-2 alpha in normal human tissues, cancers, and tumor-associated macrophages Am. J. Pathol. 157 2000 411 421
16. Q. Xu, J. Briggs, S. Park, G. Niu, M. Kortylewski, S. Zhang, T. Gritsko, J. Turkson, H. Kay, G.L. Semenza, J.Q. Cheng, R. Jove, and H. Yu Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways Oncogene 24 2005 5552 5560
17. Q. Zhang, Z.-F. Zhang, J.Y. Rao, J.D. Sato, J. Brown, D.V. Messadi, and A.D. Le Treatment with siRNA and antisense oligonucleotides targeted to Hif-1 alpha induced apoptosis in human tongue squamous cell carcinomas Int. J. Cancer 111 2004 849 857
18. R. Fukuda, K. Hirota, F. Fan, Y.D. Jung, L.M. Ellis, and G.L. Semenza IGF-1 induces HIF-1-mediated VEGF expression that is dependent on MAP kinase and PI-3-kinase signaling in colon cancer cells J. Biol. Chem. 277 2002 38205 38211
19. S. Cory, D.L. Vaux, A. Strasser, A.W. Harris, and J.M. Adams Insights from Bcl-2 and Myc: malignancy involves abrogation of apoptosis as well as sustained proliferation Cancer Res. 59 1999 1685s 1692s
20. S.A. Rosenzweig What's new in the IGF-binding proteins Growth Horm. IGF Res. 14 2004 329 336
21. X. Wu, H. Zhao, K.-A. do, M.M. Johnson, Q. Dong, W.K. Hong, and M.R. Spitz Serum levels of insulin growth factor (IGF-1) and IGF-binding protein predict risk of second primary tumors in patients with head and neck cancer Clin. Cancer Res. 10 2004 3988 3995
22. S.E. Hankinson, W.C. Willet, G.A. Colditz, D.J. Hunter, D.S. Michaud, B. Deroo, B. Rosner, F.E. Speizer, and M. Pollak Circulating concentrations of insulin-like growth factor-1 and risk of breast cancer Lancet 351 1998 1393 1396
23. J.M. Chan, M.J. Stampfer, E. Giovannucci, P.H. Gann, J. Ma, P. Wilkinson, C.H. Hennekens, and M. Pollak Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study Science 279 1998 563 566
24. H. Yu, M.R. Spitz, J. Mistry, J. Gu, W.K. Hong, and X. Wu Plasma levels of insulin-like growth factor-1 and lung cancer risk: a case-control analysis J. Natl. Cancer Inst. 91 1999 151 156
25. J. Ma, M.N. Pollak, E. Giovannucci, J.M. Chan, Y. Tao, C.H. Hennekens, and M.J. Stampfer Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-1 and IGF-binding protein-3 J. Natl. Cancer Inst. 91 1999 620 625
26. G.L. Semenza, B.H. Jiange, S.W. Leung, R. Passantino, J.P. Concordet, P. Maire, and A. Giallongo Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1 J. Biol. Chem. 271 1996 32529 32537
27. D. Mukhopadhyay, B. Knebelmann, H.T. Cohen, S. Ananth, and V.P. Sukhatme The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity Mol. Cell. Biol. 17 1997 5629 5639
28. J.G. Rheinwald, and M.A. Beckett Tumorigenic keratinocyte lines requiring anchorage and fibroblast support cultured from human squamous cell carcinomas Cancer Res. 41 1981 1657 1663
29. S.A. Robinson, and S.A. Rosenzweig Synthesis and characterization of biotinylated forms of insulin-like growth factor-1: topographical evaluation of the IGF-1/IGFBP-2 and IGFBP-3 interface Biochemistry 43 2004 11533 11545
30. M.G. Slomiany, and S.A. Rosenzweig IGF-1 induced VEGF and IGFBP-3 secretion correlates with increased Hif-1 alpha expression and activity in retinal pigment epithelial cell line D407 Invest. Ophthalmol. Vis. Sci. 45 2004 2838 2847
31. P.R. Twentyman, and M. Luscombe A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity Br. J. Cancer 56 1987 279 285
32. Y. Yuan, G. Hilliard, T. Ferguson, and D.E. Millhorn Cobalt inhibits the interaction between hypoxia-inducible factor-alpha and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-alpha J. Biol. Chem. 278 2003 15911 15916
33. M. Ui, K. Okada, K. Hazeki, and O. Hazeki Wortmannin as a unique probe for an intracellular signalling protein, phosphoinositide 3-kinase TIBS 20 1995 303 307
34. M. Favata, K.Y. Horiuchi, E.J. Manos, M.J. Daulerio, D.A. Stradley, W.S. Feeser, D.E. Van Dyk, W.J. Pitts, R.A. Earl, F. Hobbs, R.A. Copeland, R.L. Magolda, P.A. Scherle, and J.M. Trzaskos Identification of a novel inhibitor of mitogen-activated protein kinase J. Biol. Chem. 273 1998 18623 18632
35. C.E. Whittles, T.M. Pocock, S.R. Wedge, J. Kendrew, L.F. Hennequin, S.J. Harper, and D.O. Bates ZM 323881, a novel inhibitor of vascular endothelial growth factor-receptor-2 tyrosine kinase activity Microcirculation 9 2002 513 522
36. A. Viloria-Petit, T. Crombet, S. Jothy, D. Hicklin, P. Bohlen, J.M. Schlaeppi, J. Rak, and R.S. Kerbel Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis Cancer Res. 61 2001 5090 5101
37. G.L. Semenza HIF-1 and tumor progression: pathophysiology and therapeutics Trends Mol. Med. 8 2002 S62 S67
38. C. Brahimi-Horn, N. Mazure, and J. Pouyssegur Signalling via the hypoxia-inducible factor-1 alpha requires multiple posttranslational modifications Cell. Signal. 17 2005 1 9
39. J. Milanini-Mongiat, F. Vinals, J. Pouyssegur, and G. Pages Identification of two Sp1 phosphorylation sites for p42/p44 mitogen-activated protein kinases J. Biol. Chem. 277 2002 20631 20639
40. C. Neuchrist, B.M. Erovic, H. Alessandra, G.E. Steiner, P. Rockwell, C. Gedlicka, and M. Burian Vascular endothelial growth factor receptor 2 (VEGFR2) expression in squamous cell carcinomas of the head and neck Laryngoscope 111 2001 1834 1841
41. G.B. Whitaker, B.J. Limberg, and J.S. Rosenbaum Vascular endothelial growth factor receptor-2 and neuropilin-1 form a receptor complex that is responsible for the different signaling potency of VEGF165 and VEGF121 J. Biol. Chem. 276 2001 25520 25531